Dresden, Germany

Torsten Tonn

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2018-2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Work of Inventor Torsten Tonn

Introduction

Torsten Tonn is a notable inventor based in Dresden, Germany, recognized for his contributions to the field of cancer therapy. With a total of two patents to his name, Tonn's groundbreaking innovations are making strides in medical treatments, particularly through the development of specific cell therapeutic agents.

Latest Patents

Tonn's latest patents focus on the use of CAR-expressing NK-92 cells as cell therapeutic agents. His invention describes an ErbB2-specific NK-92 cell or cell line that contains a lentiviral vector encoding a chimeric antigen receptor. This innovative cell line aims to target and treat ErbB2-expressing cancers effectively. The patent outlines methods for generating and identifying these specialized cells, promoting their use in adoptive cancer immunotherapy and targeted therapeutic applications.

Career Highlights

Throughout his career, Torsten Tonn has advanced research within the realm of cancer treatment by working at various esteemed institutions. Notably, he has contributed to the Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus and the Deutsches Rotes Kreuz (DRK) Blutspendedienst Baden-Württemberg-Hessen GmbH. His involvement in these organizations underscores his commitment to innovative research aimed at improving patient outcomes in oncology.

Collaborations

In his pursuit of innovative solutions, Tonn has collaborated with esteemed professionals like Winfried Wels and Kurt Schonfeld. These alliances have played a significant role in his research endeavors, contributing to the advancement of cell-based therapeutic strategies in cancer treatment.

Conclusion

Torsten Tonn's work exemplifies the critical intersection of innovation and healthcare. His pioneering patents in CAR-expressing NK-92 cells are not just technical achievements; they represent a hope for improved cancer therapies. As he continues his research and collaboration efforts, Tonn remains a significant figure in the ongoing quest for effective cancer treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…